Prothrombin Complex Concentrate Market Size

Prothrombin Complex Concentrate Market Size

The global prothrombin complex concentrate market size was valued at around USD 2.1 billion in 2023 and is estimated to grow at 9.4% CAGR from 2024 to 2032. The increased incidence of coagulation disorders and growing demand for plasma-related therapies are driving the growth of the market.

To get key market trends

  Download Free Sample

The increased incidence of coagulation disorders is significantly driving the growth of the prothrombin complex concentrate (PCC) market globally. As the prevalence of bleeding disorders such as Hemophilia B and acquired coagulation disorders rises, the demand for effective and rapid treatments like PCC has surged. Conditions such as Vitamin K deficiency, liver disease, and the widespread use of anticoagulant therapies like warfarin, which require swift reversal in emergency situations, are also contributing to this market expansion.
 

According to the World Federation of Hemophilia (WFH) Annual Global Survey, hemophilia affects approximately 400,000 people worldwide, and about 75% of these individuals are under-treated, particularly in developing regions where access to treatment is limited. In addition, the aging global population and the rising usage of anticoagulants among elderly individuals with cardiovascular conditions are further fueling the need for PCC. With the increasing diagnosis and awareness of these disorders, the market for PCC is expected to experience robust growth in the coming years.
 

Prothrombin complex concentrate (PCC) is a medication that contains a combination of blood clotting factors. These include clotting factors II, VII, IX, and X, along with proteins C and S in some formulations. PCC is primarily used to treat or prevent bleeding in individuals with deficiencies in these factors, such as in the case of Hemophilia B (Factor IX deficiency) or for the rapid reversal of anticoagulant therapy, such as warfarin.